Abstract
Coronavirus Disease 2019 (COVID-19), caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), has created a global pandemic infecting over 230 million people and costing millions of lives. Therapies to attenuate severe disease are desperately needed. Cenicriviroc (CVC), a C-C chemokine receptor type 5 (CCR5) and C-C chemokine receptor type 2 (CCR2) antagonist, an agent previously studied in advanced clinical trials for patients with HIV or nonalcoholic steatohepatitis (NASH), may have the potential to reduce respiratory and cardiovascular organ failures related to COVID-19. Inhibiting the CCR2 and CCR5 pathways could attenuate or prevent inflammation or fibrosis in both early and late stages of the disease and improve outcomes of COVID-19. Clinical trials using CVC either in addition to standard of care (SoC; e.g., dexamethasone) or in combination with other investigational agents in patients with COVID-19 are currently ongoing. These trials intend to leverage the anti-inflammatory actions of CVC for ameliorating the clinical course of COVID-19 and prevent complications. This article reviews the literature surrounding the CCR2 and CCR5 pathways, their proposed role in COVID-19, and the potential role of CVC to improve outcomes.
【초록키워드】 COVID-19, Dexamethasone, coronavirus disease, severe acute respiratory syndrome coronavirus 2, SARS-CoV-2, Inflammation, Coronavirus disease 2019, clinical trial, Trial, clinical trials, fibrosis, outcome, severe acute respiratory syndrome Coronavirus, coronavirus 2, global pandemic, outcomes, Clinical course, clinical, pathway, complications, respiratory, Chemokine receptor, CCR5, Combination, Pathways, severe disease, Organ failure, Standard of care, agent, CCR2, acute respiratory syndrome coronavirus, anti-inflammatory action, late stage, steatohepatitis, NASH, investigational agent, anti-inflammatory actions, infecting, nonalcoholic steatohepatitis, Prevent, Cenicriviroc, IMPROVE, caused, addition, the disease, reduce, attenuate, patients with COVID-19, patients with HIV, 【제목키워드】 COVID-19, Treatment, inhibitor, Chemokine receptor, rationale,